On Monday, Nektar Therapeutics (NASDAQ: NKTR) was -7.72% drop from the session before settling in for the closing price of $64.93. A 52-week range for NKTR has been $0.43 – $66.92.
Healthcare Sector giant saw their annual sales surged by 25.49% over the last five years. When this article was written, the company’s average yearly earnings per share was at -29.65%. With a float of $18.60 million, this company’s outstanding shares have now reached $19.02 million.
Nektar Therapeutics (NKTR) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Nektar Therapeutics stocks. The insider ownership of Nektar Therapeutics is 2.18%, while institutional ownership is 49.76%. The most recent insider transaction that took place on Sep 09 ’25, was worth 311,214. In this transaction President & CEO of this company sold 6,666 shares at a rate of $46.69, taking the stock ownership to the 49,342 shares. Before that another transaction happened on Sep 09 ’25, when Company’s Officer proposed sale 6,666 for $46.69, making the entire transaction worth $311,205.
Nektar Therapeutics (NKTR) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -2.65 earnings per share (EPS) during the time that was better than consensus figure (set at -3.09) by 0.44. Wall Street market experts anticipate that the next fiscal year will bring earnings of -3.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -29.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -15.34% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
You can see what Nektar Therapeutics (NKTR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 15.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.72, a number that is poised to hit -2.68 in the next quarter and is forecasted to reach -11.51 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Analysing the last 5-days average volume posted by the [Nektar Therapeutics, NKTR], we can find that recorded value of 0.67 million was lower than the volume posted last year of 0.91 million. As of the previous 9 days, the stock’s Stochastic %D was 58.53%.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 88.12%, which indicates a significant increase from 46.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 4.94 in the past 14 days, which was higher than the 3.06 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.30, while its 200-day Moving Average is $24.36. Now, the first resistance to watch is $63.50. This is followed by the second major resistance level at $67.07. The third major resistance level sits at $70.16. If the price goes on to break the first support level at $56.84, it is likely to go to the next support level at $53.75. Now, if the price goes above the second support level, the third support stands at $50.18.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
There are 19,019K outstanding shares of the company, which has a market capitalization of 1.14 billion. As of now, sales total 98,430 K while income totals -118,960 K. Its latest quarter income was 11,180 K while its last quarter net income were -41,590 K.
